

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 31 of March 2023

	31.03.2023	31.12.2022
	<i>BGN'000</i>	<i>BGN'000</i>
ASSETS		
Non-current assets		
Property, plant and equipment	34 834	35 319
Intangible assets	3 694	3 761
Investments in subsidiaries	19	19
Trade receivables	5 076	5 076
Total non-current assets	43 623	44 175
Current assets		
Inventories	12 383	13 480
Trade and other receivables	64 511	62 056
Current corporate income tax	27	27
Cash and cash equivalents	82	126
Total current assets	77 003	75 689
Total assets	120 626	119 864
LIABILITIES		
Equity		
Share capital	84 500	84 500
Reserves	12 498	12 498
Retained earnings	6 530	4 591
Total	103 528	101 589
Non-current liabilities		
Long-term loans	1 291	1 399
Deferred tax liabilities	1 042	1 042
Retirement benefit obligations	191	191
Total non-current liabilities	2 524	2 632
Current liabilities		
Trade and other liabilities	3 773	5 079
Short-term loans	9 780	9 785
Current portion of long-term loans	554	620
Other tax liabilities	467	159
Total current liabilities	14 574	15 643
Total liabilities	17 098	18 275
Total equity and liabilities	120 626	119 864

Date of preparation: 26.04.2023

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 31 of March 2023

	31.03.2023	31.03.2022
	<i>BGN'000</i>	<i>BGN'000</i>
Revenue	13 610	12 778
Other income	30	54
Total income	13 640	12 832
Carrying amount of goods sold	(709)	(102)
Changes in inventories of finished products and work in progress	(257)	(560)
Materials and services	(7 573)	(7 735)
Personnel expenses	(1 567)	(1 371)
Depreciation / amortisation expenses	(867)	(940)
Other expenses	(468)	(73)
Finance income	27	5
Finance costs	(147)	(89)
Total expenses	(11 561)	(10 865)
Profit before taxation	2 079	1 967
Corporate income tax expense	(140)	(90)
Profit/Loss for the period	1 939	1 877
Total comprehensive income for the period	1 939	1 877
Earnings per share / in BGN per 1 share /	0.02	0.02

Date of preparation: 26.04.2023

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 31 of March 2023

	31.03.2023	31.03.2022
	<i>BGN'000</i>	<i>BGN'000</i>
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	8 489	7 570
Payments to suppliers of materials, goods and services	(4 348)	(4 498)
Payments to personnel	(1 593)	(1 343)
Foreign currency exchange gains/losses	(2)	(12)
Payments of interest and dividends	(140)	(90)
Other proceeds / payments	(1 512)	(1 079)
<i>Net cash flows</i>	894	548
Cash flows from investing activities		
Payments on non-current assets acquired	(699)	(361)
<i>Net cash flows</i>	(699)	(361)
Cash flows from financial activities		
Proceeds from loans	101	49
Payments on loans	(109)	(49)
Payment of interest, dividends	(101)	(49)
Payments on finance lease	(130)	(130)
Payments from government donations	-	-
<i>Net cash flows</i>	(239)	(179)
Change in cash and cash equivalents	(44)	8
Cash and cash equivalents at the beginning of the period	126	40
Cash and cash equivalents at the end of the period	82	48

Date of preparation: 26.04.2023

Sofia

Prepared by:.....

/ P. Moneva /

Executive

Director:.....

/B. Georgiev /

Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 31 of March 2023

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
Balance as of 01.01.2022	84 500	4 375	8 007	1 940	98 822
Profit/loss for the period				2 791	2 791
Other comprehensive income		(24)			(24)
Including from tax effect of the revaluation of property, plant and equipment					
Total comprehensive income		(24)		2 791	2 767
Issue of shares by the owners			140	(140)	
Dividends accrued			140	(140)	
Tantiemmes accrued					
Profit transferred to reserves					
Total amount of income and expenses recognised during the period					
Balance as of 31.12.2022	84 500	4 351	8 147	4 591	101 589
Balance as of 01.01.2023	84 500	4 351	8 147	4 591	101 589
Profit/loss for the period				1 939	1 939
Other comprehensive income					
Total comprehensive income				1 939	1 939
Issue of shares by the owners					
Total amount of income and expenses recognised during the period					
Balance as of 31.03.2023	84 500	4 351	8 147	6 530	103 528

Date of preparation: 26.04.2023
Sofia

Prepared by:.....
/P. Moneva/

Executive Director:.....
/B. Georgiev /